Structure Therapeutics (NASDAQ:GPCR) Trading Up 7.5% – Here’s Why

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) traded up 7.5% during trading on Wednesday . The company traded as high as $17.16 and last traded at $16.97. 584,887 shares changed hands during trading, a decline of 31% from the average session volume of 850,763 shares. The stock had previously closed at $15.79.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on GPCR shares. Stifel Nicolaus began coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price on the stock. William Blair started coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, JMP Securities restated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Up 8.4 %

The stock has a market capitalization of $981.14 million, a PE ratio of -23.12 and a beta of -2.37. The firm has a 50 day moving average price of $23.74 and a 200-day moving average price of $30.82.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Equities analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GPCR. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Structure Therapeutics in the fourth quarter worth about $3,091,000. GF Fund Management CO. LTD. purchased a new position in shares of Structure Therapeutics in the 4th quarter valued at about $34,000. Woodline Partners LP raised its holdings in Structure Therapeutics by 0.7% in the 4th quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock worth $9,055,000 after purchasing an additional 2,328 shares during the period. Vestal Point Capital LP boosted its position in Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $46,782,000 after purchasing an additional 575,000 shares in the last quarter. Finally, Twinbeech Capital LP grew its holdings in Structure Therapeutics by 34.3% in the fourth quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock valued at $767,000 after purchasing an additional 7,220 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.